240 related articles for article (PubMed ID: 32656818)
1. Therapeutic antisense oligonucleotides for movement disorders.
Doxakis E
Med Res Rev; 2021 Sep; 41(5):2656-2688. PubMed ID: 32656818
[TBL] [Abstract][Full Text] [Related]
2. Antisense therapies for movement disorders.
Scoles DR; Pulst SM
Mov Disord; 2019 Aug; 34(8):1112-1119. PubMed ID: 31283857
[TBL] [Abstract][Full Text] [Related]
3. Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders.
Silva AC; Lobo DD; Martins IM; Lopes SM; Henriques C; Duarte SP; Dodart JC; Nobre RJ; Pereira de Almeida L
Brain; 2020 Feb; 143(2):407-429. PubMed ID: 31738395
[TBL] [Abstract][Full Text] [Related]
4. Antisense therapies in neurological diseases.
Brunet de Courssou JB; Durr A; Adams D; Corvol JC; Mariani LL
Brain; 2022 Apr; 145(3):816-831. PubMed ID: 35286370
[TBL] [Abstract][Full Text] [Related]
5. Antisense oligonucleotides: the next frontier for treatment of neurological disorders.
Rinaldi C; Wood MJA
Nat Rev Neurol; 2018 Jan; 14(1):9-21. PubMed ID: 29192260
[TBL] [Abstract][Full Text] [Related]
6. [Antisense therapies for neurological diseases].
Pulst SM
Nervenarzt; 2019 Aug; 90(8):781-786. PubMed ID: 31165208
[TBL] [Abstract][Full Text] [Related]
7. Antisense oligonucleotides: A primer.
Scoles DR; Minikel EV; Pulst SM
Neurol Genet; 2019 Apr; 5(2):e323. PubMed ID: 31119194
[TBL] [Abstract][Full Text] [Related]
8. Antisense Drugs Make Sense for Neurological Diseases.
Bennett CF; Kordasiewicz HB; Cleveland DW
Annu Rev Pharmacol Toxicol; 2021 Jan; 61():831-852. PubMed ID: 33035446
[TBL] [Abstract][Full Text] [Related]
9. Translating Antisense Technology into a Treatment for Huntington's Disease.
Lane RM; Smith A; Baumann T; Gleichmann M; Norris D; Bennett CF; Kordasiewicz H
Methods Mol Biol; 2018; 1780():497-523. PubMed ID: 29856033
[TBL] [Abstract][Full Text] [Related]
10. Antisense oligonucleotides in neurological disorders.
Wurster CD; Ludolph AC
Ther Adv Neurol Disord; 2018; 11():1756286418776932. PubMed ID: 29854003
[TBL] [Abstract][Full Text] [Related]
11. Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease.
Sardone V; Zhou H; Muntoni F; Ferlini A; Falzarano MS
Molecules; 2017 Apr; 22(4):. PubMed ID: 28379182
[TBL] [Abstract][Full Text] [Related]
12. Making sense of antisense oligonucleotides: A narrative review.
Goyal N; Narayanaswami P
Muscle Nerve; 2018 Mar; 57(3):356-370. PubMed ID: 29105153
[TBL] [Abstract][Full Text] [Related]
13. Antisense Oligonucleotide Therapy for the Nervous System: From Bench to Bedside with Emphasis on Pediatric Neurology.
Amanat M; Nemeth CL; Fine AS; Leung DG; Fatemi A
Pharmaceutics; 2022 Nov; 14(11):. PubMed ID: 36365206
[TBL] [Abstract][Full Text] [Related]
14. A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration.
Monine M; Norris D; Wang Y; Nestorov I
J Pharmacokinet Pharmacodyn; 2021 Oct; 48(5):639-654. PubMed ID: 33991294
[TBL] [Abstract][Full Text] [Related]
15. Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases.
Holm A; Hansen SN; Klitgaard H; Kauppinen S
RNA Biol; 2022; 19(1):594-608. PubMed ID: 35482908
[TBL] [Abstract][Full Text] [Related]
16. Lowering Mutant Huntingtin Using Tricyclo-DNA Antisense Oligonucleotides As a Therapeutic Approach for Huntington's Disease.
Imbert M; Blandel F; Leumann C; Garcia L; Goyenvalle A
Nucleic Acid Ther; 2019 Oct; 29(5):256-265. PubMed ID: 31184975
[TBL] [Abstract][Full Text] [Related]
17. Oligonucleotide therapeutics in neurodegenerative diseases.
Scoles DR; Pulst SM
RNA Biol; 2018; 15(6):707-714. PubMed ID: 29560813
[TBL] [Abstract][Full Text] [Related]
18. Drug Discovery Perspectives of Antisense Oligonucleotides.
Kim Y
Biomol Ther (Seoul); 2023 May; 31(3):241-252. PubMed ID: 36859811
[TBL] [Abstract][Full Text] [Related]
19. Better living through peptide-conjugated chemistry: next-generation antisense oligonucleotides.
McNally EM; Leverson BD
J Clin Invest; 2019 Nov; 129(11):4570-4571. PubMed ID: 31566581
[TBL] [Abstract][Full Text] [Related]
20. Antisense oligonucleotide-based therapies for diseases caused by pre-mRNA processing defects.
Rigo F; Seth PP; Bennett CF
Adv Exp Med Biol; 2014; 825():303-52. PubMed ID: 25201110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
